Antibody data
- Antibody Data
- Antigen structure
- References [2]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- NBP1-02935 - Provider product page
- Provider
- Novus Biologicals
- Proper citation
- Novus Cat#NBP1-02935, RRID:AB_1520301
- Product name
- Rabbit Polyclonal ATF3 Antibody
- Antibody type
- Polyclonal
- Description
- Immunogen affinity purified.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 0.1 ml
- Concentration
- 1.27 mg/ml
- Storage
- Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Submitted references Activation of ATF4 mediates unwanted Mcl-1 accumulation by proteasome inhibition.
Activation of the c-Jun N-terminal kinase/activating transcription factor 3 (ATF3) pathway characterizes effective arylated diazeniumdiolate-based nitric oxide-releasing anticancer prodrugs.
Hu J, Dang N, Menu E, De Bruyne E, Xu D, Van Camp B, Van Valckenborgh E, Vanderkerken K
Blood 2012 Jan 19;119(3):826-37
Blood 2012 Jan 19;119(3):826-37
Activation of the c-Jun N-terminal kinase/activating transcription factor 3 (ATF3) pathway characterizes effective arylated diazeniumdiolate-based nitric oxide-releasing anticancer prodrugs.
Maciag AE, Nandurdikar RS, Hong SY, Chakrapani H, Diwan B, Morris NL, Shami PJ, Shiao YH, Anderson LM, Keefer LK, Saavedra JE
Journal of medicinal chemistry 2011 Nov 24;54(22):7751-8
Journal of medicinal chemistry 2011 Nov 24;54(22):7751-8
No comments: Submit comment
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: ATF3 Antibody [NBP1-02935] - Western blot analysis of ATF3 on UV treated NIH/3T3 cell extracts using NBP1-02935.
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Immunohistochemistry: ATF3 Antibody [NBP1-02935] - Analysis of ATF3 in human prostate using Fast Red with hematoxylin counterstain.